Clinical Trial

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Summary
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
Protocol Amendment History 3 changes
notable Trial sites expanded: 58 -> 62 locations 2026-07-19
notable Primary completion pushed: 2027-04-30 -> 2028-02-28 2026-07-19
minor Completion pushed: 2027-04-30 -> 2028-02-28 2026-07-19
Trial Details
NCT Number NCT06723106
Lead Sponsor Chugai Pharmaceutical
Conditions Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Enrollment 144 participants
Start Date 2024-12-09
Primary Completion 2028-02-28 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-17